Advertisement

Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey

  • J. P. M. Finberg
  • J. Wang
  • K. Bankiewicz
  • J. Harvey-White
  • I. J. Kopin
  • D. S. Goldstein
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)

Summary

Striatal extracellular fluid concentrations of dopamine and metabolites in response to direct striatal administration of two L-DOPA boluses administered sequentially were determined in three rhesus monkeys during halothane anesthesia. Whereas in an initial microdialysis run, generation of dopamine was less following the second L-DOPA bolus than the first, in a subsequent run, in which the selective MAO-B inhibitor R(+)-Npropargyl-1-aminoindan (rasagiline) was administered systemically (0.2 mg/ kg s.c.) between the two L-DOPA boluses, generation of dopamine was greater following the second bolus.

Keywords

Monoamine Oxidase Microdialysis Probe Monoamine Oxidase Activity DOPAC Level Dopamine Efflux 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the antiakinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303–326PubMedCrossRefGoogle Scholar
  2. Colzi A, D’Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum; a microdialysis study. J Neural Transm [Suppl] 32: 79–84Google Scholar
  3. Di Monte DA, De Lanney LE, Irwin LE, Royland JE, Chan P, Jalowec MW, Langston JW (1996) Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys. Brain Res 738: 53–59PubMedCrossRefGoogle Scholar
  4. Finberg JPM, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN-1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65–74PubMedCrossRefGoogle Scholar
  5. Finberg JPM, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS (1995) Influence of selective inhibiton of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213–1220PubMedCrossRefGoogle Scholar
  6. Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic “suicide” and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73: 55–64PubMedCrossRefGoogle Scholar
  7. Knoll J (1978) The possible mechanisms of action of (—)-deprenyl in Parkinson’s disease. J Neural Transm 43: 177–198PubMedCrossRefGoogle Scholar
  8. Parkinson’s Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371Google Scholar
  9. Paterson IA, Davis BA, Durden BA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA (1995) Inhibition of MAO-B by (—)-deprenyl alters dopamine metabolism in the macaque (macaca fascicularis) brain. Neurochem Res 20: 1503–1510PubMedCrossRefGoogle Scholar
  10. Richards JG, Saura J, Luque JM, Cesurs AM, Gottowik J, Malherbe P, Borroni E, Gray J (1997) Monoamine oxidases: from brainmaps to physiology and transgenics to pathophysiology (this volume)Google Scholar
  11. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of Parkinson patients treated with l-deprenyl. J Neurochem 46: 1359–1365PubMedCrossRefGoogle Scholar
  12. Riederer R, Reynolds JP, Youdim MBH (1981) Selectivity of MAO inhibitors in human brain and their clinical consequences. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. Wiley, Chichester, pp 63–76Google Scholar
  13. Tipton KF, Houslay MD, Mantle TJ (1976) The nature and locations of the multiple forms of monoamine oxidase. Elsevier, Amsterdam, pp 5–16 (Ciba Foundation Symposium 39)Google Scholar
  14. Wachtel SR, Abercrombie E (1994) L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108–117PubMedCrossRefGoogle Scholar
  15. Wang J, Skirboll S, Aigner TG, Saunders RC, Bankiewicz KS (1990) Methodology of microdialysis of neostriatum in hemiparkinsonian non-human primates. Exp Neurol 110: 181–186PubMedCrossRefGoogle Scholar
  16. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • J. P. M. Finberg
    • 1
    • 2
  • J. Wang
    • 1
  • K. Bankiewicz
    • 1
  • J. Harvey-White
    • 1
  • I. J. Kopin
    • 1
  • D. S. Goldstein
    • 1
  1. 1.Clinical Neurosciences Branch and Surgical NeurologyNINDS, NIHBethesdaUSA
  2. 2.Pharmacology UnitFaculty of Medicine, TechnionHaifaIsrael

Personalised recommendations